CLINICAL TRIALS PROFILE FOR DARINAPARSIN
✉ Email this page to a colleague
Clinical Trials for Darinaparsin
| Trial ID | Title | Status | Sponsor | Phase | Summary |
|---|---|---|---|---|---|
| NCT00303199 ↗ | Study of ZIO-101 in Multiple Myeloma | Completed | Ziopharm | Phase 1/Phase 2 | The study of safety of a new organic arsenic compound in the treatment of advanced multiple myeloma |
| NCT00421213 ↗ | Phase II Study of ZIO-101 in Advanced Blood and Bone Marrow Cancers | Completed | Ziopharm | Phase 2 | The study of safety of a new organic arsenic compound in the treatment of hematological malignancies. |
| NCT00423306 ↗ | A Phase-II Trial of ZIO 101 in Advanced Hepatocellular Carcinoma | Unknown status | Ziopharm | Phase 2 | The study of safety of a new organic arsenic compound in the treatment of advanced hepatocellular carcinoma |
| NCT00591396 ↗ | A Phase I Trial of ZIO-101 in Solid Tumors | Completed | Ziopharm | Phase 1 | A Phase I Trial of ZIO-101 (Darinaparsin) in Solid Tumors |
| NCT00591422 ↗ | Phase I Study of Oral Darinaparsin (ZIO-101-C)in Advanced Solid Tumors and Non-Hodgkin's Lymphomas | Unknown status | Ziopharm | Phase 1 | The study of Dariniparsin (ZIO-101-C) in Advanced Solid Tumors and Non-Hodgkin's Lymphomas |
| NCT00592046 ↗ | A Phase I Trial of ZIO-101 in Hematologic Cancers | Completed | Ziopharm | Phase 1 | This study uses a new investigational (not yet approved by the FDA for widespread use) drug called ZIO-101, an organic arsenical. You must be diagnosed to have relapsed/refractory leukemia or lymphoma (blood cancer) and have tried other standard therapies. This study is designed to determine whether ZIO-101 may be given safely. The study will also test whether ZIO-101 helps to treat blood cancer. We anticipate that approximately 22 to 35 patients will take part in this study. Arsenic has been used as a medicinal agent for centuries in many different cultures. Most recently in the United States, an inorganic arsenic compound was approved by the FDA for the treatment of patients with relapsed acute promyelocytic leukemia (APL). However, use of inorganic arsenic is limited by a narrow range of activity and systemic toxicity, most notably of the cardiac system. ZIO-101 is an organic arsenic derivative. In vitro testing in both the National Cancer Institute (NCI) cancer cell panel and in vivo testing in a leukemia animal model demonstrated substantial activity of SGLU against hematologic cancers. In vitro testing of SGLU using the NCI human cancer cell panel also detected activity against lung, colon and brain cancers, melanoma, and ovary and kidney cancers. Moderate activity was seen against breast and prostate cancers cells. Data suggest that organic arsenic generates reactive oxygen species in the cells to induce apoptosis and cell cycle arrest. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Summary |
Clinical Trial Conditions for Darinaparsin
Condition Name
Clinical Trial Locations for Darinaparsin
Trials by Country
Clinical Trial Progress for Darinaparsin
Clinical Trial Phase
Clinical Trial Sponsors for Darinaparsin
Sponsor Name
